Article

Barries in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World-Evidence Scenario

2021-09-27

Abstract excerpt

BACKGROUND Precision oncology has a prominent role in nonsquamous non-small cell lung cancer (nsNSCLC) treatment progress. This study aimed to investigate not-cost-related factors involved in the use of the molecular profile in clinical practice and the influence of its availability on clinical decisions. METHODS nsNSCLC patients who underwent molecular testing in a private referral Brazilian center were identif...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 060b6f4c-9ca7-55cf-8e75-e29d4e4b7ce9
DOI: 10.21203/rs.3.rs-927396/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Barries in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World-Evidence ScenarioDOI 10.21203/rs.3.rs-927396/v1Read

Precision Oncology: Who, How, What, When, and When Not?Semantic proximity Read

Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.Semantic proximity Read

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).Semantic proximity Read

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).Semantic proximity Read

Real-World Study on Implementation of Genomic Tests for Advanced Lung Adenocarcinoma in Brazil.Semantic proximity Read

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.Semantic proximity Read

Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country.Semantic proximity Read

Impact of Molecular Biomarker Test Availability and Timing on Metastatic Non-Small-Cell Lung Cancer Treatment Selection and Clinical Outcomes in the U.S. Medicare PopulationSemantic proximity Read

Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.Semantic proximity Read

The evolving paradigm of precision medicine in lung cancer.Semantic proximity Read

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).Semantic proximity Read

Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.Semantic proximity Read